FUTURE OF HEALTHCARE

Iris Telehealth Engages Amendola for Strategic PR and Media Relations Services

Amendola Communications | April 27, 2022

Iris Telehealth

Amendola Communications, a nationally recognized, award-winning healthcare and technology marketing and public relations firm, announced that Iris Telehealth, a leading provider of telepsychiatry services for community mental health centers, community health centers, hospitals, and health systems across the U.S., has selected the firm to manage PR, media relations, and thought leadership. Iris conducted an extensive agency search and selected Amendola for its successful track record, industry acumen, and bench strength.

"The COVID-19 pandemic has magnified the importance of addressing mental health as a part of overall public health. Providing easy and convenient access to accredited psychiatric services from quality behavioral health professionals is essential to this effort. Iris Telehealth's use of telemedicine to expand clinically sound psychiatric services to patients and healthcare organizations is making a tangible impact in this regard, and we're enthused to help execute their vision of enabling a better world through healthy minds."

agency CEO Jodi Amendola

Amendola is implementing a comprehensive public relations, thought leadership, communications, and media plan for Iris Telehealth that will showcase its value proposition, services, accomplishments, customer wins, and industry partnerships. The agency successfully kicked off the relationship by supporting the Austin, Texas-based company's recent Series B funding. Amendola garnered significant media coverage for this major milestone, including an audience reach of more than 61 million via placements in high-profile healthcare trade and business media such as MobiHealthNews, MedCity News, Digital Health Business and Technology, Axios, Fortune, and STAT as well as local Austin media.

"There's a nationwide need to provide timely, quality behavioral healthcare, and our track record shows we can help health systems and community organizations sustainably improve care for their communities," said Dan Ferris, Chief Marketing Officer of Iris Telehealth. "We're teaming up with Amendola Communications to drive awareness of our unique value to the healthcare market and our mission of supporting the mental wellbeing of patient populations that need it most. Our Series B announcement was our first effort to gain more market awareness and we know that with Amendola's help, this is just the beginning." 

Iris Telehealth has grown exponentially over the last 18 months as healthcare organizations seek to provide timely, quality care to their patients. Iris's combination of high-quality providers, best-in-class support, expertise to optimize care models, and technology has enabled customers to reimagine how behavioral health services are provided across the continuum of care.

About Amendola Communications
Amendola is an award-winning, insights-driven public relations and marketing firm that integrates media relations, social media, content, and lead gen programs to move healthcare, life sciences/pharma and healthcare IT decision-makers to action. The agency represents some of the industry's best-known brands as well as groundbreaking startups that are disrupting the status quo. Nearly 90% of its client base represents multi-year clients and/or repeat client executives. Amendola's seasoned team of PR and marketing pros understand the ongoing complexities of the healthcare ecosystem and provide strategic guidance and creative direction to drive positive ROI, boost reputation and increase market share. Making an impact since 2003, Amendola combines traditional and digital media to fuel meaningful and measurable growth. 

About Iris Telehealth 
Iris Telehealth helps healthcare organizations consistently increase access to quality mental healthcare for their patients by providing the clinicians, staff support, and knowledge to build a sustainable telepsychiatry department. With clinical grounding and emphasis on human relationships, Iris Telehealth identifies best-fit providers for each unique organization and ensures long-term commitment to meeting their partner's needs, allowing them to provide the highest quality care to their patients and community. 

Spotlight

Although the volume of alcohol consumed is a clear indicator of potential harm to health, other factors affect the relationship.


Other News
HEALTH TECHNOLOGY

Prospection partners with leading Japanese healthcare data provider Medical Data Vision to improve treatment access for patients

Prospection | September 06, 2022

Health analytics pioneer, Prospection has announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. to accelerate healthcare analytics globally. The agreement, covering the world's second largest pharmaceutical market, will provide global pharmaceutical companies and researchers access to comprehensive and longitudinal data covering more than 40 million people in Japan at more than 470 hospitals. Combining predictive analytics and machine learning with real-world healthcare data, Prospection's agreement with MDV will provide pharmaceutical companies across the world with unique access to patient diagnostic and medication data from hospitals across Japan, unlocking potential to assess an unlimited number of treatment programs in the region. The agreement also enables access to patient history and prefecture level data, allowing analysis of disease progression, disease outcomes and the mapping of disease courses to provide evidence on areas where development can address unmet needs. When distilled further, this creates an opportunity to assess patient data on a regional level to find geographical areas where patients or health centres require additional support for specific disease and conditions. Prospection's access to Japan's most comprehensive medical data sets is a significant milestone for the company. Prospection currently provides real-time access to longitudinal patient data across 15 regions globally including Australia, New Zealand, Japan, South Korea, Taiwan, USA and the UK. The company's latest announcement with Medical Data Vision will build on this work, providing Prospection with access to one of Japan's largest healthcare databases. "We are delighted to announce our latest agreement with Medical Data Vision. This partnership demonstrates a shared commitment to improving patient outcomes and marks a significant milestone in Prospection's mission to deliver real community benefits to patients across the globe. "As one of the largest pharmaceutical markets in the world, Japan has incredibly rich datasets. Working with Medical Data Vision gives us the opportunity to access a dataset of approximately 40 million patients, creating a unique opportunity to use advanced analytic tools to accelerate precision medicine to enable the right patient to receive the right treatment at the right time in their journey. "The outcomes of this partnership will play a key role in understanding the full cycle of patient health conditions and disease journeys in areas including immuno-oncology, immune disorders, cardiovascular and metabolic conditions allowing researchers and pharmaceutical companies globally to better understand the different patient characteristics, treatments and respective outcomes." Eric Chung, CEO and Co-founder, Prospection "We are very excited to be working with MDV in our latest data access agreement. Combining MDV's large and comprehensive dataset with Prospections global reach and extensive expertise working with datasets across the world will not only allow MNC pharmaceutical companies to work with patient data from Japan, but will also open a broader understanding of different health conditions across the world. This agreement brings us one step closer to enhancing precision medicine to find the 40% of patients that can be optimised." About Prospection Prospection is a pioneer in health data analytics technology. We are on a mission to make advancements to precision medicine through real world evidence, with an aim to put the right patient on the right treatment at the right time. Applying advanced ML algorithms to real-world data we unearth health journey and treatment insights by analysing longitudinal data for hundreds of millions of patients to see how drug treatments are used after the clinical trial. Delivering actionable real-world evidence that enables better outcomes for patients, across the world. Prospection is guided by credentialled experts and innovative leaders within their respective fields. Globally, we work with over 15 large health data sets applying our expertise to examine health patterns. Working with government and researchers through to our core client base in the pharma/biopharmaceutical industry, we have delivered insights across more than 90 therapeutic indications. Including rare and complex diseases such as oncology, immuno-oncology, virology, metabolic conditions, respiratory and cardiovascular disease. Prospection is backed by investors including Ellerston, Horizons Ventures and Main Sequence, and commercially with CRO Novotech. About Medical Data Vision (MDV) MDV is an accumulation of anonymously processed data with secondary usage permission from medical institutions. The actual number of patients in the "hospital data" centered on the acute phase is 40.42 million. In addition, by holding data from the health insurance association, data on the recovery period and chronic period has been enhanced, and in addition to information by hospital/clinic, it has become possible to track information on transfer destinations. "Health insurance data" was 7.84 million people (same).

Read More

HEALTH TECHNOLOGY

VBA Partners With Healthcare Bluebook to Provide Enhanced Reporting of Quality Data for Physicians and Hospitals

Healthcare Bluebook and VBA | September 09, 2022

VBA, a leading-edge healthcare technology company, has teamed up with Healthcare Bluebook to incorporate Quantros quality scores for over half a million physicians and hospitals into its VBAnalytics reporting solution. This move is just one of many exciting enhancements around quality-based care reporting planned in 2022 to make VBAnalytics the premier population health and business insight solution for healthcare payers. VBAnalytics already provides robust analysis and reporting of healthcare utilization and costs and offers insight to help payers make the necessary changes to ensure their health plans are performing effectively. “As the healthcare industry continues to strive for transparency in both cost and quality, the Quantros quality data is essential for our clients to remain competitive. Being able to benchmark their results against millions of healthcare claims from all regions of the country provides invaluable insight to manage their plan performance.” Michael Clayton, President and CEO of VBA With VBAnalytics Value-Based Care Reporting, powered by Quantros, health plans can easily combine cost and quality data to determine which providers are performing the best under their value-based care arrangements. Equipped with this information, payers can make adjustments to their provider networks to ensure that patients have access to the best providers. The Quantros quality scores include important measures of physician and hospital performance including patient safety, complications from a procedure or hospitalization, mortality, and hospital readmissions. Data is combined among multiple providers to create an episode of care, which allows for a more comprehensive view of the patient’s experience. VBA has also integrated Healthcare Bluebook’s online shopping tool within its VBAGateway member portal to make it simple for members to access cost and quality information they need with just a few clicks. “When consumers are equipped with accurate information on cost and quality, everybody wins,” said Clayton. “As consumers become more educated about their healthcare decisions, it will lead to more thoughtful choices that can have a positive ripple effect throughout the healthcare system.” Providing consumers with better information also helps to reduce the overall cost of healthcare for employers, who cover a significant portion of the healthcare costs for their employees. About VBA VBA is a leading-edge healthcare technology company providing comprehensive solutions to the insurance industry. Uniquely delivered on a secure, cloud-based platform, VBA provides a suite of technology solutions for benefits administration, user experience, customer support, business insight and more. About Healthcare Bluebook Healthcare Bluebook's purpose is to protect consumers and companies nationwide from overpriced, low-quality healthcare. Since 2007, Healthcare Bluebook has helped millions of people by making it easy for them to find high-quality care at a Fair Price™.

Read More

FUTURE OF HEALTHCARE

Concord Health Partners Adds Healthcare Veteran Brian Gragnolati as Executive Partner

Concord Health Partners | July 12, 2022

Concord Health Partners a healthcare focused investment firm, announced that Brian Gragnolati has joined as Executive Partner. Gragnolati currently serves as President and CEO of Atlantic Health System. During his tenure at Atlantic Health System, he also served as Chairman of the Board of Trustees of the American Hospital Association. The addition of Gragnolati as Executive Partner further expands Concord's team of healthcare sector specialists, adding the network, knowledge and insights of an experienced CEO and a nationally recognized leader in the provider industry. Gragnolati will work with James Olsen, Founder and Managing Partner, and other members of the Concord team to source new investment opportunities, support management teams and accelerate the growth of portfolio companies through commercial introductions across the Concord network of strategic relationships. "We are thrilled to add someone with Brian's experience, knowledge and expertise to Concord's executive team. We established Concord with the goal of creating lasting partnerships with strategic investors to help drive the adoption of our portfolio company technologies and solutions across a broad universe of healthcare providers and payors. Brian brings unique perspective from his roles as a health system chief executive officer and at the AHA, and has distinguished himself as a valuable partner to Concord in those roles. We look forward to leveraging his insights and network as he helps identify new opportunities and accelerate growth at our portfolio companies as Executive Partner." James Olsen, Founder and Managing Partner at Concord "In working with Concord over the years, it was clear that the Firm has developed a powerful model for healthcare investing. Concord has become a leader in identifying innovative companies and partnering with them to drive growth," said Gragnolati. "I am excited at the opportunity to work even more closely with the Concord team and their portfolio companies to help them continue to deliver solutions that lower costs, improve quality and expand access to care." Gragnolati has served as President and CEO of Atlantic Heath System since 2015, and is the former Chairman of the Board of Trustees of the AHA. Prior to his tenure at Atlantic Health, Brian served as Senior Vice President at Johns Hopkins Medicine. He previously held executive positions at Wellspan Health, University of Vermont Medical Center and Baystate Medical Center in Springfield, MA. As a nationally respected voice in health care, Mr. Gragnolati played a key role in public relations and media communications during the COVID pandemic. He regularly appears on CNBC, MSNBC, Bloomberg and other media outlets to share his insight on the nation's most pressing health concerns. He has been honored by Modern Healthcare as one of the 100 most influential people in healthcare. He serves on the Board of Directors of Lakeland Bancorp, Inc. and Lakeland Bank. Gragnolati holds a bachelor's degree in Health Systems Analysis from the University of Connecticut, an MBA from Western New England College and an Executive Leadership Certificate from the JFK School at Harvard University. About Concord Health Partners Concord Health Partners is a healthcare focused investment firm with a strategic model that optimizes the alignment of interests between investors and portfolio companies. Concord has developed a broad network of strategic investors that contribute expertise and resources, and serve as potential commercial partners to portfolio companies. Concord is primarily focused on investing in healthcare companies that have the potential to enhance the value of care through products, services, technologies and solutions that lower costs, improve quality and expand access to care.

Read More

HEALTH TECHNOLOGY

Aktana Welcomes New Medical Affairs Lead from IBM Watson Health (Now Merative)

Aktana | September 28, 2022

Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes Deepak Patil as its new senior director of medical strategy. Patil comes to Aktana after leadership roles at IBM Watson Health, IQVIA, and Sun Pharma Industries where he managed medical affairs in conjunction with six key product launches and developed lasting relationships with key opinion leaders in targeted therapeutic areas. At Aktana, Patil will lead the company’s medical affairs program, initially helping to build modern, data-driven solutions for medical science liaisons but over time, also expand to other areas within medical affairs. Medical Affairs is the “third strategic pillar of the pharmaceutical organization alongside R&D and commercial, as science and data merge,” according to a McKinsey report. Business models are starting to evolve both around and beyond the “product” to encompass the wider therapeutic context, while organizations seek to explain and contextualize the ever more complex medical science to a diverse range of stakeholders. In outreach efforts, MSLs and commercial teams can unintentionally overlap, causing major compliance issues and frustrating doctors. Aktana’s intelligence solutions will not only help medical affairs improve key opinion leader relationships but also better orchestrate outreach to the physician community in compliance with regional engagement regulations. “Deepak brings a unique blend of medical experience – he received his medical degree in India – plus data science and operational expertise from IQVIA and IBM. As we prioritize new, AI-driven solutions for medical affairs teams, Deepak will help expertly shape our new offerings while building a powerhouse team focused on this increasingly important area of life sciences.” Clay Hausmann, chief revenue officer at Aktana Aktana has also announced a strategic partnership with Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs. Envision and Aktana will combine their offerings to help MSLs address HCP demands for personalized scientific content and coordinated omnichannel engagement. “Aktana is committed to enabling the medical affairs organization in a new era, and I’m excited to serve in a leadership role as part of this endeavor,” said Deepak Patil. “The real-world data is there. With the right technology, we have the power to improve the generation and dissemination of scientific insights to physicians, leading to better treatment decisions and outcomes for their patients.” With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 platform is powered by the company’s next-generation Contextual Intelligence Engine, which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements that will deliver the highest ROI. About Aktana Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world.

Read More

Spotlight

Although the volume of alcohol consumed is a clear indicator of potential harm to health, other factors affect the relationship.

Resources